From: THE MEDICAL NEWS
A new therapy that reduces the risk of mortality and heart failure
in patients with mild cardiac disease received a thumb's up this
week from an advisory panel to the U.S. Food and Drug
Administration. The panel recommended that the cardiac
resynchronization therapy defibrillator (CRT-D), tested extensively
nationwide under the leadership of cardiologist Arthur Moss, M.D.,
professor of Medicine at the University of Rochester Medical
Center, be approved for use in patients with mild heart failure in
the United States.
Respond to this topic on your own blog
Click and press Ctrl+C to copy and paste this discussion on your blog or site
Related Articles
Avandia Raises Heart Risk, FDA Panel Finds
A U.S. government advisory panel weighing the fate of the diabetes
drug Avandia has voted that the medication does raise users' odds
for heart attack more than other medications of its kind but does
not increase the risk of death. A decision on whether or not the
drug should be banned from the market is expected by late Wednesday
at the end of the two-day meeting.
Gene therapy improve survival rates among heart attack patients
Gene therapy could be an effective way to improve survival rates
among heart attack patients, new research funded by the British
Heart Foundation (BHF) suggests. Academics at the University of
Bristol found that boosting levels of a natural growth factor in
the heart could help the muscle to recover after a heart attack.
The death rate from a heart attack was halved in mice that received
the treatment.
Celladon Corporation receives USPTO notice of allowance covering MYDICAR for advanced heart failure
Celladon Corp. announced today that the United States Patent and
Trademark Office (USPTO) has granted a notice of allowance for a
broad patent covering the company's lead drug candidate
MYDICAR®, a genetically targeted enzyme replacement
therapy for advanced heart failure. The patent will be issued to
The Regents of the University of California and licensed
exclusively to Celladon.
Noninvasive monitoring of cardiac allograft vasculopathy with fast MR imaging
Cardiac allograft vasculopathy (CAV), also known as chronicle
rejection, is a leading cause of graft (foreign heart) loss and
death in patients who survive the first year after heart
transplantation. The typical pathological change of CAV is
gradually thickening of coronary wall in "foreign" heart due to
continuous immunological reaction between donated heart and the
host. In some cases, undetected CAV may silently cause graft
failure with global myocardial ischemia without any documented
infarction signs. Thus, continually monitoring development of
asymptomatic CAV is important for selecting prophylactic strategies
to get better prognosis. However, most current examinations of
detecting CAV are invasive and with certain risks.
The Sex Drug Chronicles: Flibanserin Evidence Too Flimsy for FDA Approval
An FDA advisory panel last week unanimously recommended not to
approve a new drug that purports to treat hypoactive sexual desire
disorder (HSDD) in women, which is defined as “low or no
sexual interest to the point of distress in otherwise healthy
people.” According to Julia Johnson, the panel’s
chairwoman and head of the department of [...]
